🌍 New global cancer statistics from American Cancer Society & IARC reveal that ~20 million new cancer cases were diagnosed in 2022 and 9.7 million people died from the disease worldwide. Cancer cases are predicted to reach 35 million by 2050. acsjournals.onlinelibrary.wiley.com/doi/10.3322/ca… OncoAlert

🎊What a great way to start the week❗️😃 🎊I am super excited & humbled to be featured in the #RisingStars section of the April 2024 Issue of the Oncology Compass Digest. Mine is a story of #mentorship & #sponsorship! Full article: 🔗:oncologycompass.com/digest/issue9/… #FlorezLab 🫶

🩺 Until the 19th century, esophageal cancer was deemed incurable. 💡 Breakthroughs like the esophagoscope improved diagnostics. 👨‍⚕️ Progress in surgery, Barrett's esophagus ID, and endoscopy have enhanced treatment. #Oncology #OncologyCompass

Proud to share a big team effort on "Recommendations for reporting tissue and circulating tumour (ct)DNA next-generation sequencing results in non-small cell lung cancer published in British Journal of Cancer pubmed.ncbi.nlm.nih.gov/38750115/

See the #openaccess article by Umberto Malapelle, Christian Rolfo & colleagues who have provided best practice recommendations for the reporting of NGS results in #NSCLC to assist its use, allowing for easy interpretation for physicians 🫁 ➡️ nature.com/articles/s4141…

This week, our spotlight is on a pivotal study assessing the efficacy of tebentafusp in patients with metastatic uveal melanoma. Read more: oncologycompass.com/articles/three… #melanoma

#ASCO24 Many expanding options after chemo-IO failure in 2L #NSCLC ☑️ Pattern of IO resistance matters! ☑️ NGS testing imperative for all- rebiopsy! ☑️ TKIs, ADCs (HER2, cMET) ☑️ Biomarker-driven platform trials needed! ☑️ Mind the algorithm! #some #LCSM ASCO ESMO - Eur. Oncology IASLC

Really important stage shift shown in Taiwan National Lung screen program. Bravo Dr PC Yang! Family hx is a key risk factor. Excited to collaborate with Allison Chang and Jill Feldman to open a clinical trial soon focused on screening in those w/ a positive family hx #ASCO24

So many powerhouses in one picture! #ASCO24 you were great once again! OncoAlert

As an US oncologist, it was a super fun time discussing how #ASCO24 lung cancer data can impact our practice with Alfredo Addeo MD (Switzerland) and Lizza Hendriks (Netherland). EMA and US FDA allow very different options for oncologists. EGFR Resisters MD Anderson Cancer Center Exon 20 Group, a multi-stakeholder organization

THEOREMM: A Novel Framework for Cancer Registration Trials. "Trials in HEmatology and Oncology REviewed by Metaresearch Methods" drugdevletter.com/p/theoremm-a-n… via Vinay Prasad MD MPH & Timothée Olivier, MD

Excited to share that the July issue of Annals of Oncology features our work on the cover! Read the ETOP IBCSG Partners Foundation position statement on antibody-drug conjugates in lung and breast cancer: current evidence and future directions. #BCSM #LCSM annalsofoncology.org/article/S0923-…

Our new blog about treatment of patients with early hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) #breastcancer is live, read more here: oncologycompass.com/blog/post/ribo…

New issue #10 of the 'Digest' is out now! 📣 Featuring a Ewing Sarcoma survival story, the Direct Primary Care model and advances in HER2-positive breast cancer treatments. Stay informed with the latest oncology updates: oncologycompass.com/digest/issue10/ #CancerResearch #Oncology

Join us for the 6th International Lung Cancer Summit (#ILCS24), live in Lausanne or online, with our hosts Solange Peters and Alfredo Addeo MD alongside leading world experts to discuss the latest advances in thoracic oncology. 🗓️ 4th Oct 2024 from 10AM CET Secure your seat now ⬇️

According to IARC, #lungcancer is the most common cancer globally with 2.5M new cases (12.4%) and the leading cause of cancer death (18.7%). Awareness and early detection is crucial. Explore resources: oncologycompass.com/publications?f… #WorldLungCancerDay

Immunotherapy has reshaped cancer treatment paradigm, but we still need biomarkers for patient selection This paper on Nature Cancer introduces an approach using multi-omics data and machine learning to improve patient selection for IO OncoAlert nature.com/articles/s4301…

We are pleased with the publication of the Neo-Real study (GBECAM-0123), which evaluated RWD from 10 Brazilian centers, comparing ddAC vs q3wAC regimen in pts with #TNBC treated with #pembrolizumab plus CT in the neoadjuvant setting. rdcu.be/dQX6E

Editorial The Lancet Respiratory Medicine questions role of anti-CTLA-4 for mNSCLC after phase III NIPPON trial stopped early for toxicity. Great points from Drs. Molly Li Stephanie Saw Alfredo Addeo MD. Perhaps use of STK11/KEAP1 as selection, would avoid in PDL1 high. thelancet.com/journals/lanre…

First described in the 19th century, #AppendixCancer remains a rare and challenging disease to diagnose. Raising awareness is essential to improve early detection and patient outcomes. #AppendixCancerAwareness